A Study of S-1 in Combination With Gemcitabine as First-Line Treatment in Patients With Advanced Biliary Tract Cancer
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 16 Jul 2017
At a glance
- Drugs Gimeracil/oteracil/tegafur (Primary) ; Gemcitabine
- Indications Biliary cancer
- Focus Therapeutic Use
- Sponsors TTY Biopharm
- 05 Jul 2017 Planned End Date changed from 1 Jun 2017 to 1 Aug 2017.
- 06 Feb 2017 Status changed from recruiting to active, no longer recruiting.
- 11 Jan 2016 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.